反応 #1726711

ord-087b3c62b7454b1ba7e430bc3da69298

反応方程式

O=C1CCNCC1
4-piperidone
Cc1ccc(O)c(C(N)=O)c1
2-hydroxy-5-methylbenzamide
C1COCCN1
morpholine
Cc1ccc2c(c1)C(=O)NC1(CCNCC1)O2
Compound 137
Cc1ccc2c(c1)C(=O)NC1(CCNCC1)O2
6-methylspiro-[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one

反応条件

詳細条件
See reaction.notes.procedure_details.

後処理

  1. 1
    温度is refluxed for 20 hr
  2. 2
    洗浄washed with water, brine
  3. 3
    乾燥dried over Na2SO4
  4. 4
    その他After solvent removal by rotoevaporation
  5. 5
    その他the crude product is purified by preparative TLC

実験手順

A mixture of 26 mg (0.083 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone (prepared as described in Example 44), 12.5 mg (0.083 mmol) of 2-hydroxy-5-methylbenzamide, and 0.020 mL of morpholine in 2 mL of methanol is refluxed for 20 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 20 mg (0.045 mmol, 54% yield) of 1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]-6-methylspiro-[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one (Compound 137): 1H NMR (DMSO-d6): δ 2.28 (s, 3H), 3.95 (s, 3H), 4.06 (s, 3H), 6.98 (d, 1H), 7.19 (s, 1H), 7.23 (d of d, 1H), 7.33 (d of d, 1H), 7.52 (d of d, 1H), 7.56 (d, 1H), 7.68 (d of d, 1H), and 8.77 ppm (s, 1H). MS m/z: 448.1 (M+H)+, 470.0 (M+Na)+.

出典

DOI: 10.6084/m9.figshare.5104873.v1特許: US08110570B2uspto-grants-2012_02